FDA Orange Book · active-ingredient family
Afamelanotide
Afamelanotide is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:SCENESSE · NDA 210797
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
1
Exclusivity periods
Brand (NDA) products · implant
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SCENESSERLD | CLIVUNEL INC | NDA 210797 | — | Oct 08, 2019 |
Marketing exclusivity (1)
- ODE-270Orphan-drug exclusivity (7 years)
Oct 08, 2026
in 4 mo
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8334265 | Jan 20, 2033 | in 6 yr 8 mo | U-2638 |
Afamelanotide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

